Business Description
Outlook Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US69012T2069
Description
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.28 | |||||
Equity-to-Asset | -1.12 | |||||
Debt-to-Equity | -1.5 | |||||
Debt-to-EBITDA | -0.7 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 22.8 | |||||
3-Year EPS without NRI Growth Rate | 29 | |||||
3-Year FCF Growth Rate | 26.8 |
Momentum Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 52.45 | |||||
9-Day RSI | 51.38 | |||||
14-Day RSI | 51.6 | |||||
6-1 Month Momentum % | 63.71 | |||||
12-1 Month Momentum % | -54.79 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.44 | |||||
Quick Ratio | 0.44 | |||||
Cash Ratio | 0.23 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -27 | |||||
Shareholder Yield % | -10.61 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROA % | -119.68 | |||||
ROIC % | -156.2 | |||||
ROC (Joel Greenblatt) % | -32738.99 | |||||
ROCE % | -1871.94 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
EV-to-EBIT | -4.31 | |||||
EV-to-EBITDA | -4.31 | |||||
EV-to-Forward-Revenue | 173.98 | |||||
EV-to-FCF | -4.76 | |||||
Earnings Yield (Greenblatt) % | -23.2 | |||||
FCF Yield % | -23.79 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Outlook Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -3.708 | ||
Beta | -1.22 | ||
Volatility % | 194.65 | ||
14-Day RSI | 51.6 | ||
14-Day ATR (€) | 0.349142 | ||
20-Day SMA (€) | 7.96575 | ||
12-1 Month Momentum % | -54.79 | ||
52-Week Range (€) | 3.58 - 36.8 | ||
Shares Outstanding (Mil) | 23.3 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Outlook Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Outlook Therapeutics Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Outlook Therapeutics Inc Frequently Asked Questions
What is Outlook Therapeutics Inc(FRA:41O)'s stock price today?
When is next earnings date of Outlook Therapeutics Inc(FRA:41O)?
Does Outlook Therapeutics Inc(FRA:41O) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |